Highlights in melanoma from ASCO 2024

Immunotherapy significantly increases the number of patients free from bowel cancer

Encouraging results using mismatched unrelated donors in stem cell transplantation

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy

Importance of MRD in newly developed multiple myeloma

ASCO 2024: Lung cancer roundup

Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple myeloma

Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer

ASCO 2024: Highlights and analysis